

FORM PTO-1449

**INFORMATION DISCLOSURE CITATION**

Attorney Docket  
23105-B

Serial Number  
Not Yet Assigned

Applicant  
STEINER et al.

Filing Date  
April , 2001

Group Art Unit

**U.S. PATENT DOCUMENTS**

Examiner Initial		Document Number	Date	Name	Class	Sub-Class	Filing Date
<i>N</i>	AA	5,532,248	7/2/96	Goulet et al.			5/12/95
	AB	5,506,228	4/9/96	Norton et al.			2/23/95
	AC	5,470,878	11/28/95	Michnick et al.			12/8/93
	AD	5,457,111	10/10/95	Luly et al.			11/9/93
	AE	5,385,918	1/31/95	Connell et al.			2/9/93
	AF	5,342,625	8/30/94	Hauer et al.			12/15/92
	AG	5,292,747	3/8/94	Davis et al.			9/21/92
	AH	5,284,877	2/8/94	Organ et al.			6/12/92
	AI	5,284,840	2/8/94	Rupprecht et al.			6/12/92
	AJ	5,284,826	2/8/84	Eberle			8/27/92
<i>N</i>	AK	5,258,389	11/2/93	Goulet et al.			11/9/92

**FOREIGN PATENT DOCUMENTS**

		Document Number	Date	Country	Class	Sub-Class	Translation
<i>h</i>	AL	WO 97/36869	10/09/97	WO PCT			Yes
<i>h</i>	AM	WO 96/41609	12/27/96	WO PCT			Yes
<i>h</i>	AN	564 924 A2	10/13/93	EP EP			Yes
<i>h</i>	AO	423 714 A2	4/24/91	EP EP			Yes
	AP						Yes No

**OTHER** (Including Author, Title, Date, Pertinent Pages, etc.)

<i>h</i>	AR	Birkenshaw, T.N. et al., "Synthetic FKBP12 Ligands. Design and Synthesis of Pyranose Replacements," <u>Bioorganic &amp; Medicinal Chemistry Letters</u> , (1994) 4:21, 2501-2506.
	AS	Caffrey, M.V. et al., "Synthesis and Evaluation of Dual Domain Macrocyclic FKBP12 Ligands," <u>Bioorganic &amp; Medicinal Chemistry Letters</u> , (1994) 4:21, 2507-2510.
<i>N</i>	AT	Hauske, J.R. et al., "Design and Synthesis of Novel FKBP Inhibitors," <u>J. of Medicinal Chemistry</u> , (1992) 35, 4284-4296.

Examiner

*ACorb*

Date Considered

*9/12/01*

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP § 609.  
Draw line through citation if not in conformance and not considered.  
Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE CITATIONAttorney Docket  
23105-BSerial Number  
Not Yet Assigned

Applicant

STEINER et al.

Filing Date  
April , 2001

Group Art Unit

## U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Sub-Class	Filing Date
n	BA	5,208,241	5/4/93	Ok et al.			9/9/91
	BB	5,192,773	3/9/93	Armistead et al.			7/2/90
	BC	5,189,042	2/23/93	Goulet et al.			8/22/91
	BD	4,996,193	2/26/91	Hewitt et al.			3/3/89
	BE	5,614,547	3/25/97	Hamilton et al.			6/7/95
	BF	4,945,093	7/31/90	Maignan, et al.			7/29/88
n	BG	5,236,950	8/17/93	Aoyama, et al.			2/17/89
	BH						
	BI						
	BJ						
	BK						

## FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub-Class	Translation
	BL						Yes No
	BM						Yes No
	BN						Yes No
	BO						Yes No
	BP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

n	BR		Holt, D.A. et al., "Design, Synthesis, and Kinetic Evaluation of High-Affinity FKBP Ligands and the X-Ray Crystal Structures of Their Complexes with FKBP12," <u>J. Am. Chem. Soc.</u> , (1993) 115, 9925-9938.
	BS		Holt, D.A. et al., "Structure-Activity Studies of Synthetic FKBP Ligands as Peptidyl-prolyl Isomers Inhibitors," <u>Bioorganic &amp; Medicinal Chemistry Letters</u> , (1994) 4:2, 315-320.
n	BT		Holt, D.A. et al., "Structure-Activity Studies of Nonmacrocyclic Rapamycin Derivatives," <u>Bioorganic &amp; Medicinal Chemistry Letters</u> , (1993) 3:10, 1977-1980.

Examiner

Q Cook

Date Considered

9/12/07

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP § 609.  
 Draw line through citation if not in conformance and not considered.  
 Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE CITATIONAttorney Docket  
23105-BSerial Number  
Not Yet AssignedApplicant  
STEINER et al.Filing Date  
April , 2001

Group Art Unit

## U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Sub-Class	Filing Date
	CA						
	CB						
	CC						
	CD						
	CE						
	CF						
	CG						
	CH						
	CI						
	CJ						
	CK						

## FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub-Class	Trans-lation
	CL						Yes No
	CM						Yes No
	CN						Yes No
	CO						Yes No
	CP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

h	CR		Luengo, J.I. et al., "Synthesis and Structure-Activity Relationships of Macrocyclic FKBP ligands," <u>Bioorganic &amp; Medicinal Chemistry Letters</u> , (1994) 4:2, 321-324.
	CS		Snyder, S.H. et al., "Immunophilins and the Nervous System," <u>Nature Medicine</u> , (1995) 1:1, 32-37.
	CT		Teague, S.J. et al., "Synthesis and Study of a Non-Macrocyclic FK506 Derivative," <u>Bioorganic &amp; Medicinal Chemistry Letters</u> , (1994) 4:13, 1581-1584.

Examiner

R Cook

Date Considered

9/12/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP § 609.  
 Draw line through citation if not in conformance and not considered.  
 Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE CITATIONAttorney Docket  
23105-BSerial Number  
Not Yet AssignedApplicant  
STEINER et al.Filing Date  
April , 2001

Group Art Unit




## U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Sub-Class	Filing Date
	DA						
	DB						
	DC						
	DD						
	DE						
	DF						
	DG						
	DH						
	DI						
	DJ						
	DK						

## FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub-Class	Translation
	DL						Yes No
	DM						Yes No
	DN						Yes No
	DO						Yes No
	DP						Yes No

**OTHER** (Including Author, Title, Date, Pertinent Pages, etc.)

	DR		Teague, S.J. et al., "The Affinity of the Excised Binding Domain of FK-506 for the Immunophilin FKBP12," <u>Bioorganic &amp; Medicinal Chemistry Letters</u> , (1993) 3:10, 1947-1950.
	DS		Wang, G.T. et al., "'Synthesis and FKBP Binding of Small Molecule Mimics of the Tricarbonyl Region of FK506," <u>Bioorganic &amp; Medicinal Chemistry Letters</u> , (1994) 4:9, 1161-1166.
	DT		Yamashita, D.S. et al., "Design, Synthesis and Evaluation of Dual Domain FKBP Ligands," <u>Bioorganic &amp; Medicinal Chemistry</u> , (1994) 4:2, 325-328.

Examiner

*R Corde*

Date Considered

*9/12/01*

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP § 609.  
 Draw line through citation if not in conformance and not considered.  
 Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE CITATIONAttorney Docket  
23105-BSerial Number  
Not Yet AssignedApplicant  
STEINER et al.Filing Date  
April , 2001

Group Art Unit



**U.S. PATENT DOCUMENTS**

Examiner Initial	Document Number	Date	Name	Class	Sub-Class	Filing Date
EA						

**FOREIGN PATENT DOCUMENTS**

Document Number	Date	Country	Class	Sub-Class	Translation
EB					Yes No

**OTHER** (Including Author, Title, Date, Pertinent Pages, etc.)

	EC	Iwabuchi, T. et al., "Effects of immunosuppressive peptidyl-prolyl cis-trans isomerase (PPIase inhibitors) cyclosporin A, FK506, ascomycin and rapamycin, on hair growth initiation in mouse: immunosuppression is not required for hair growth," <u>J. of Dermatol. Sci.</u> , (1995) 9:1, 64-69.
	ED	Yamamoto, S. et al., "Stimulation of hair growth by topical application of FK506, a potent immunosuppressive agent," <u>J. Invest. Dermatol.</u> , (1994) 102:2, 160-164.
	EE	Jiang, H. et al., "Induction of anagen in telogen mouse skin by topical application of FK506, a potent immunosuppressant," <u>J. Invest. Dermatol.</u> , (1995) 104:4, 523-525.
	EF	CA 113:103206 (Aoyama, et al., U.S. Patent No. 5,236,950), August 25, 1989.
	EG	CA 118:233885 (Koga, et al., PCT Publication WO9214439), September 2, 1992.
	EH	CA 111:134182 (Maignan, et al., U.S. Patent No. 5,034,387), February 9, 1989.
	EI	CA 125:293042 (Ahluwalia, et al., PCT Publication WO9626712, U.S. Patent No. 6,093,748), Sept. 6, 1996.

Examiner



Date Considered

9/12/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP § 609.  
 Draw line through citation if not in conformance and not considered.  
 Include copy of this form with next communication to Applicant.